LM Advisors’s AbCellera Biologics ABCL Stock Holding History

LM Advisors’s Portfolio ABCL Stock Details ABCL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-200	Closed	-$1.14K	–	219
2023 Q4	$1.14K	Buy	+200	New	+$927	﹤0.01%	694

Other funds holding ABCL

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

VOYA Investment Management Atlanta, Georgia $116B AUM 61.47% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FFVM

Founders Fund VII Management San Francisco, California $2.03M AUM 72.34% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

LM Advisors's ABCL Position: Q1 2024 in Review

LM Advisors sold out of AbCellera Biologics (ABCL) in Q1 2024, closing a stake of 200 shares — an estimated $1.14K sold.

LM Advisors first reported a position in ABCL in Q4 2023 and held it in 1 quarter. The position peaked at $1.14K in Q4 2023. 154 funds tracked by Wall St. Rank hold ABCL as of Q1 2024.

LM Advisors reported no remaining AbCellera Biologics position as of Q1 2024 after selling out during the quarter.
LM Advisors sold 200 AbCellera Biologics shares in Q1 2024, an estimated $1.14K.
LM Advisors first reported a position in AbCellera Biologics in Q4 2023 and held it in 1 quarter.
LM Advisors's AbCellera Biologics position peaked at $1.14K in Q4 2023.
154 funds tracked by Wall St. Rank held AbCellera Biologics as of Q1 2024.

Based on LM Advisors's 13F filing for Q1 2024, filed 15 May 2024.